SEC Company Response from SAB Biotherapeutics, (SABS) — Jan 5, 2026
SAB Biotherapeutics, Inc.
Date: Jan. 5, 2026 · CIK: 0001833214 · Accession: 0001193125-26-002599
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292482
Letter
RE: SAB Biotherapeutics, Inc. Registration Statement on Form S-3 File No. 333-292482 Filed December 29, 2025
January 5, 2026 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549
In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Securities Act”), SAB Biotherapeutics, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to January 7, 2026 at 5:00 p.m., Eastern Time, or as soon as thereafter practicable. In making this acceleration request, the Registrant acknowledges that it is aware of its responsibilities under the Securities Act. Please call Brian Lee of Dentons US LLP at (212) 768-6926 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
SAB Biotherapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP January 5, 2026 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: SAB Biotherapeutics, Inc. Registration Statement on Form S-3 File No. 333-292482 Filed December 29, 2025 In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Securities Act”), SAB Biotherapeutics, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to January 7, 2026 at 5:00 p.m., Eastern Time, or as soon as thereafter practicable. In making this acceleration request, the Registrant acknowledges that it is aware of its responsibilities under the Securities Act. Please call Brian Lee of Dentons US LLP at (212) 768-6926 to confirm the effectiveness of the Registration Statement or with any questions. Very truly yours, SAB Biotherapeutics, Inc. /s/ Samuel J. Reich Samuel J. Reich Chief Executive Officer cc: Ilan Katz, Dentons US LLP Wing Shing (Brian) Lee, Dentons US LLP US_ACTIVE\123165070\V-1